1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Biogen’s quarterly profit jumps but stock falls

Discussion in 'BiogenIdec' started by anonymous, Apr 24, 2018 at 11:16 AM.

  1. anonymous

    anonymous Guest

    Biogen, whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings.
    Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of $5.54 per share, marking a modest improvement from $3.46 per share during the same quarter last year.
    Weeks back, Biogen along with its South Korean partner Samsung Bioepis put an end to the long-running fight with AbbVie, over the biosimilar version of the latter’s key drug Humira. https://news.alphastreet.com/biogens-quarterly-profit-jumps-but-stock-falls/